Down syndrome and leukemia: Disease biology and current treatment approaches

Children with Down syndrome have a significantly elevated risk of developing acute leukemia, particularly myeloid types, with distinct mutational patterns and treatment challenges compared to non-DS populations. Current evidence from animal and stem cell models is advancing understanding of leukemia initiation mechanisms in DS, while clinical strategies focus on balancing efficacy against chemotherapy toxicity specific to this population.